The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine

Naunyn Schmiedebergs Arch Pharmacol. 1993 Nov;348(5):486-90. doi: 10.1007/BF00173207.

Abstract

The effects of the non-NMDA glutamate receptor antagonist GYKI 52466 (2.4 and 4.8 mg/kg, i.p.) on spontaneous locomotor activity and haloperidol-induced catalepsy (0.5 mg/kg, i.p.) were assessed in naive rats and in rats pretreated with the NMDA antagonist dizocilpine (0.08 mg/kg, i.p.). GYKI 52466 given alone did not alter locomotor activity and haloperidol-induced catalepsy, but significantly antagonized the dizocilpine-induced locomotor stimulation and counteracted the anti-cataleptic effects of dizocilpine on haloperidol-induced catalepsy. Thus blockade of non-NMDA glutamate receptors antagonized the behavioural stimulant effects of a NMDA receptor blockade.

MeSH terms

  • Animals
  • Anti-Anxiety Agents*
  • Benzodiazepines / pharmacology*
  • Catalepsy / chemically induced*
  • Catalepsy / prevention & control
  • Dizocilpine Maleate / antagonists & inhibitors*
  • Dizocilpine Maleate / pharmacology
  • Excitatory Amino Acid Antagonists*
  • Haloperidol / toxicity
  • Male
  • Motor Activity / drug effects*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors*

Substances

  • Anti-Anxiety Agents
  • Excitatory Amino Acid Antagonists
  • Receptors, N-Methyl-D-Aspartate
  • GYKI 52466
  • Benzodiazepines
  • Dizocilpine Maleate
  • Haloperidol